Funding Opportunities for Test Method Developers
NICEATM and ICCVAM seek to facilitate development of test methods that replace, reduce, and refine the use of animals in testing. In addition, both organizations are committed to the protection of human health, animal health, and the environment. This page lists announcements of funding opportunities intended to support the development of alternative test methods. If you are aware of a funding opportunity that could be included on this page, please contact NICEATM.
SBIR and STTR Omnibus Grant Solicitations of the National Institutes of Health, Centers for Disease Control and Prevention, and Food and Drug Administration
NIEHS is offering funding for small businesses developing technologies of interest to the Tox21 program. These technologies include:
- Improved or expanded testing methods for toxicity screening
- Computational approaches for predictive toxicology
- Technologies such as alternative or improved methods for fixing and preserving tissues
The funding is being offered as part of the 2019 Omnibus Solicitation of the NIH, CDC, and Food and Drug Administration. This funding is available for small business grant applications to support development and commercialization of innovative technologies. View more information on the NIEHS website.
SBIR/STTR Omnibus Solicitations and Accompanying Resources
- Solicitation notices on NIH website (posted May 8, 2019)
- Program Descriptions and Research Topics
- Appendix A (SBA approved topics for budget waivers)
- Application Guide for SBIR/STTR Grant Applications
Next due date: January 5, 2020
For more information about this opportunity, contact:
NIH Funding Resources
The NIEHS SBIR/STTR Program Staff encourages applicants to submit grants at least one week before the deadline and to take advantage of the following resources:
- NIH "All About Grants" Podcast on the Office of Extramural Research website
- NIH RePORTER Matchmaker – useful for an initial screen for matching your technology to an institute and a relevant study section for review. It is also a great place to better understand what types of technologies NIH institutes fund.
- NIH Grants Policy Statement – rules for applying for and accepting a grant
- Frequently Asked Questions about SBIR and STTR grants on the NIH website
- Frequently asked questions about SBIR/STTR grants in general
- Annotated SBIR/STTR SF424 application forms
- Webinar series for funding opportunities for environmental technologies
- NIH study section identifier – allows you to search your topic of interest
- Application cover letters are optional but provide you an opportunity to designate an institute or study section
- Rules for calculating number of employees
- Registration and application instructions (this process can take six to eight weeks and should be initiated well before the deadline)
- Top five eRA Commons errors
NIEHS Providing Funding to Develop In Vitro Models
NIEHS will provide funding for U.S. small businesses to develop novel, engineered 3D or organotypic in vitro systems using cells from experimental animal models typically used for toxicology testing. When developed and validated, these animal-derived in vitro systems will help predict toxicity of chemical and drug candidates, enable comparisons with existing in vivo animal toxicity data, and potentially reduce the numbers of animals used in toxicology testing.
The funding opportunity is open only to U.S. small businesses. NIEHS intends to fund six to eight awards totaling up to $4 million. Applications for renewals of existing grants are eligible. While this project is intended to facilitate comparisons to in vivo animal data, applicants should not include new in vivo animal studies in their research plan for initial development of these models. Letters of intent are due December 3, with applications due January 3, 2020.
NIH Commercialization Readiness Pilot Program
The NIH Commercialization Readiness Pilot program facilitates the commercialization of previously funded SBIR and STTR Phase II and Phase IIB projects by funding activities not typically supported through Phase II or Phase IIB grants or contracts. Small businesses that have had an active NIH SBIR or STTR Phase II or Phase IIB award within the last 36 months are eligible to apply. Awardees will receive up to $300,000. Standard SBIR/STTR application deadlines apply for these grants; the next deadline is January 5, 2020.
NIH to Fund Studies to Improve iPSC Reproducibility
NIH is offering SBIR grants to develop methods that improve the reproducibility of human induced pluripotent stem cell (iPSC) derivation, growth, and differentiation. Eligible projects should seek to address the significant variability currently observed in human iPSCs in reprogramming efficiency, differentiation potential, and cell growth and stability, which is limiting the full potential of these tools for research and clinical practice. Eleven NIH Institutes and centers, including NIEHS, intend to commit funds to this effort, with an estimated 25 awards to be awarded to U.S. small businesses. Applications will be accepted from December 6, 2019 through January 6, 2020.